Liraglutide for adults living with obesity
Review (24 RCTs, n=9937) found liraglutide likely increases proportion of people achieving ≥5% weight loss at medium‐term follow‐up, and be sustained longer‐term. It may lead to an increase in adverse events, which might limit sustainability of initial effects.
Source:
Cochrane Database of Systematic Reviews
Further information:
Cochrane reviews of semaglutide and tirzepatide for adults living with obesity have also been published.